Eurofins Scientific SE News - ERF

FeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing

CORRECTING and REPLACING: Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 April 2022

Regulatory News: This replaces the announcement made at 1:56 PM CEST on May 3 due to the following corrections: "Exercise of stock options and...

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 April 2022

Regulatory News: Eurofins (Paris:ERF): ANNEXE B Form to be used for the disclosure of the total number of voting rights and capital, in...

Eurofins Core Business1 Delivers Strong Organic Revenue Growth in Q1 2022, in Line With Its Recently Upgraded Organic Growth2 Objective of 6.5% p.a.

Q1 2022 revenues of €1,760m, +9.1% vs. Q1 2021, despite a significant decrease in COVID related revenues Q1 2022 total revenue organic growth2...

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 March 2022

Regulatory News: Eurofins Scientific SE (Paris:ERF): ANNEXE B Form to be used for the disclosure of the total number of voting rights and...

EUROFINS SCIENTIFIC SE : AVIS DE CONVOCATION DES ACTIONNAIRES A L’ASSEMBLEE GENERALE ORDINAIRE ANNUELLE ET A L’ASSEMBLEE GENERALE EXTRAORDINAIRE DE LA SOCIETE VALANT AVIS D’INFORMATION DES OBLIGATAIRES

Regulatory News: EUROFINS SCIENTIFIC SE (Paris:ERF): Les actionnaires de la Société, et uniquement avec voix consultative les porteurs de...

Eurofins Genomics wird die Genotypisierung von bis zu 5 Millionen Teilnehmern an „Our Future Health“, dem bislang größten Gesundheitsforschungsprogramm des Vereinigten Königreichs, durchführen

Eurofins (Paris:ERF): Eurofins Genomics wird Our Future Health, das bislang größte Gesundheitsforschungsprogramm des Vereinigten Königreichs...

Eurofins Genomics réalisera le génotypage de 5 millions de participants au programme Our Future Health, le plus grand du genre pour la recherche en santé jamais mis en place au Royaume-Uni.

Eurofins (Paris : ERF) : Eurofins Genomics est fier d'annoncer son soutien à Our Future Health, le plus grand programme de recherche en santé...

Eurofins Genomics Will Be Conducting Genotyping for up to 5 Million Participants of Our Future Health, UK’s Largest Ever Health Research Programme

Eurofins (Paris:ERF): Eurofins Genomics is proud to announce its support for Our Future Health, the UK’s largest ever health research programme...

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 28 February 2022

Regulatory News: ANNEXE B Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and...

Eurofins Significantly Exceeds Its Objectives in 2021 and Increases Its Objectives for 2022 and 2023

Regulatory News: Eurofins Scientific (Paris:ERF): Financial Highlights Eurofins delivered a very strong performance in FY 2021, exceeding all...

Eurofins acquiert Genetic Testing Service JSC et pénètre sur le marché des tests génétiques cliniques au Vietnam

Eurofins Scientific («Eurofins») (Paris : ERF), leader scientifique mondial dans le domaine des tests bioanalytiques et du diagnostic clinique...

Eurofins to Acquire Genetic Testing Service JSC and Enter the Clinical Genetic Testing Market in Vietnam

Regulatory News: Eurofins Scientific (“Eurofins”) (Paris:ERF), a global scientific leader in bioanalytical testing and clinical diagnostics...

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 January 2022

Regulatory News: Eurofins Scientific SE (Paris:ERF): ANNEXE B Form to be used for the disclosure of the total number of voting rights and...

empowerDX, filiale d’Eurofins lance PFAS Exposure™ aux États-Unis, premier test sanguin effectué à domicile pour détecter et mesurer plus de 40 perfluorés (PFAS)

Aujourd’hui, empowerDX, filiale d’Eurofins (Paris:ERF), a lancé PFAS Exposure™ aux États-Unis, premier test effectué à domicile par le...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Eurofins Scientific SE (ERF)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

ERF News

FeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing

CORRECTING and REPLACING: Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 April 2022

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 April 2022

Eurofins Core Business1 Delivers Strong Organic Revenue Growth in Q1 2022, in Line With Its Recently Upgraded Organic Growth2 Objective of 6.5% p.a.

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 March 2022

EUROFINS SCIENTIFIC SE : AVIS DE CONVOCATION DES ACTIONNAIRES A L’ASSEMBLEE GENERALE ORDINAIRE ANNUELLE ET A L’ASSEMBLEE GENERALE EXTRAORDINAIRE DE LA SOCIETE VALANT AVIS D’INFORMATION DES OBLIGATAIRES

Eurofins Genomics wird die Genotypisierung von bis zu 5 Millionen Teilnehmern an „Our Future Health“, dem bislang größten Gesundheitsforschungsprogramm des Vereinigten Königreichs, durchführen

Eurofins Genomics réalisera le génotypage de 5 millions de participants au programme Our Future Health, le plus grand du genre pour la recherche en santé jamais mis en place au Royaume-Uni.

Eurofins Genomics Will Be Conducting Genotyping for up to 5 Million Participants of Our Future Health, UK’s Largest Ever Health Research Programme

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 28 February 2022

Eurofins Significantly Exceeds Its Objectives in 2021 and Increases Its Objectives for 2022 and 2023

Eurofins acquiert Genetic Testing Service JSC et pénètre sur le marché des tests génétiques cliniques au Vietnam

Eurofins to Acquire Genetic Testing Service JSC and Enter the Clinical Genetic Testing Market in Vietnam

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 January 2022

empowerDX, filiale d’Eurofins lance PFAS Exposure™ aux États-Unis, premier test sanguin effectué à domicile pour détecter et mesurer plus de 40 perfluorés (PFAS)

ERF Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Eurofins Scientific SE (ERF) News

Eurofins Scientific SE (ERF)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

ERF News

FeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing

CORRECTING and REPLACING: Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 April 2022

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 April 2022

Eurofins Core Business1 Delivers Strong Organic Revenue Growth in Q1 2022, in Line With Its Recently Upgraded Organic Growth2 Objective of 6.5% p.a.

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 March 2022

EUROFINS SCIENTIFIC SE : AVIS DE CONVOCATION DES ACTIONNAIRES A L’ASSEMBLEE GENERALE ORDINAIRE ANNUELLE ET A L’ASSEMBLEE GENERALE EXTRAORDINAIRE DE LA SOCIETE VALANT AVIS D’INFORMATION DES OBLIGATAIRES

Eurofins Genomics wird die Genotypisierung von bis zu 5 Millionen Teilnehmern an „Our Future Health“, dem bislang größten Gesundheitsforschungsprogramm des Vereinigten Königreichs, durchführen

Eurofins Genomics réalisera le génotypage de 5 millions de participants au programme Our Future Health, le plus grand du genre pour la recherche en santé jamais mis en place au Royaume-Uni.

Eurofins Genomics Will Be Conducting Genotyping for up to 5 Million Participants of Our Future Health, UK’s Largest Ever Health Research Programme

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 28 February 2022

Eurofins Significantly Exceeds Its Objectives in 2021 and Increases Its Objectives for 2022 and 2023

Eurofins acquiert Genetic Testing Service JSC et pénètre sur le marché des tests génétiques cliniques au Vietnam

Eurofins to Acquire Genetic Testing Service JSC and Enter the Clinical Genetic Testing Market in Vietnam

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 January 2022

empowerDX, filiale d’Eurofins lance PFAS Exposure™ aux États-Unis, premier test sanguin effectué à domicile pour détecter et mesurer plus de 40 perfluorés (PFAS)

ERF Discussion

Your Recent History